Skip to Main Content
(Press Enter)

Environmental, Social
and Governance Report

Transforming patients’ lives through science

As a leading biopharma company, we understand our responsibility extends well beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases. We believe that driving long-term business value is at the heart of living our purpose—being leaders and difference-makers for generations to come.

Our evolving ESG strategy builds on a legacy of comprehensive and global sustainability efforts, encompassing the products we make and how we make them, our facilities, our employees and our communities.

Ethics, Integrity
& Quality

We are committed to ethics, integrity and quality in everything we do for patients, customers and colleagues.

We operate with effective governance and the highest ethical standards. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs.

Innovation & Access
to HealthCare

Our comprehensive company strategy to inclusively discover, develop and deliver innovative medicines requires us to apply a health equity lens to the way we do business across the product life cycle.

Our People

We value diversity
and inclusion.

We embrace the belief that diverse experiences and an inclusive culture yield transformative business results. The health, safety, equitable and respectful treatment of our workforce, people development and work-life balance are among our highest priorities.


We honor our longstanding pledge to environmental sustainability.

We understand our responsibility to create maximum positive impact while minimizing our environmental footprint. We leverage sustainability to drive innovation, build resiliency and manage non-financial risks.

In 2020, we developed our ESG strategy and reinforced our commitment to Health Equity, Diversity and Inclusion and Environmental Responsibility through the creation of bold new targets for our business.

Read more from our Board Chair and CEO Giovanni Caforio, M.D.

Our Public Commitments

2020 ESG Highlights

In 2020, we evolved our ESG strategy to mobilize combined capabilities
and resources to positively impact the communities where we live, work and serve.

Now viewing slide 1 of 4

Slide 1: Enhancing

Slide 2: Innovative

Slide 3: Accelerating
Commitment to
Diversity & Inclusion

Slide 4: Expanding

Continued to disclose the average net selling price increase for our U.S. products for 2020, approximately 1% across our combined company products (Bristol Myers Squibb and Celgene).

Issued Global Diversity & Inclusion Report.

Published Sustainability Accounting Standards Board (SASB) Index elevating our disclosure and in line with industry best practice.

Published inaugural report on our anti-corruption compliance program based on guidance from Norges Bank Investment Management and the Basel Institute on Governance.

Launched Opdivo (nivolumab) + Yervoy (ipilimumab) dual Immuno-Oncology for first-line lung cancer.

Launched three new medicines for serious diseases:

  • Zeposia (ozanimod) for multiple sclerosis.
  • Onureg (azacitidine tablets) for treatment of acute myeloid leukemia.
  • Reblozyl* (luspatercept-aamp) for treatment of anemia inpatients with myelodysplastic syndromes (MDS).

*Collaboration with Acceleron Pharma Inc.

Established new Health Equity and Diversity & Inclusion commitments.

Refreshed and deepened our focus on unconscious bias workshops for global leadership team, managers and employees.

Spent more than $695 million globally with diverse business enterprises, striving toward our goal of $1 billion by 2025.

Met or exceeded all 19 targets in support of our five Sustainability 2020 Goals.

Launched new 2030 and 2040 Environmental Goals, including 100% energy purchased from renewable sources, net neutral GHG emissions, and zero waste to landfill.

Named as U.S. Environmental Protection Agency ENERGY STAR Partner of the Year: Sustained Excellence for the seventh consecutive year as of April 21, 2021.

Avoided the generation of >1,000MT chemical process across nine projects (2016-2020) through Green Chemistry efforts.

This is Bristol Myers Squibb’s inaugural environmental, social and governance (ESG) report, written in accordance with the Biopharma Investor ESG Communications Guidance 2.0, developed by the Biopharma Investor ESG Communications Initiative, part of the Biopharma Sustainability Roundtable (BSR). The BSR is a sector-specific collaboration network with participants from 12 global biotech and pharma companies and 14 institutional investors. The Biopharma Investor ESG Communications Initiative addresses the shared interest of leading biopharma companies and investors in more effective, efficient and decision-useful communications about the sector’s highest-priority ESG issues. It facilitates an ongoing industry-investor dialog that builds consensus around the information needed to manage and assess biopharma sector ESG performance. Inspired by the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-Related Financial Disclosures (TCFD), the initial Biopharma Investor ESG Communications Guidance (Guidance 2.0) released in April 2020 is being followed for this report. This report also includes our first Anti-Corruption report using the Norges Bank Investment Management (NBIM) guidance.

This report consolidates and aligns our longstanding reporting on sustainability performance with current standards to provide additional transparency to our progress in this critical area. This report also includes our response to the Global Reporting Initiative (GRI), NBIM, and the SASB requirements for the biopharmaceutical sector.

All data in this report represent work conducted in 2020, except where noted.

The Global Reporting Initiative (GRI) Norges Bank Investment Management (NBIM) Sustainability Accounting Standards Board (SASB)

Throughout the COVID-19 pandemic, Bristol Myers Squibb has focused on ensuring the continued supply of our medicines to our patients and protecting the health, wellbeing and safety of our workforce. We are also participating in partnerships and research efforts to advance diagnostics and treatments for COVID-19 and supporting relief efforts across the globe. Here are some highlights of our response efforts:

Here are some highlights

For a more in-depth look,
download the full report.

Download Report